Shire Gains Renovo’s Skin Scarring Candidate Through Licensing Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Total value of the deal could reach $825 million, pending regulatory approval and sales milestones.
You may also be interested in...
U.K. Biotech Renovo's Future On The Line As Phase III Lead Crashes
The Phase III failure of Renovo's scar reduction treatment threatens the company's future and is the latest in a string of bad news for U.K. biotech.
U.K. Biotech Renovo's Future On The Line As Phase III Lead Crashes
The Phase III failure of Renovo's scar reduction treatment threatens the company's future and is the latest in a string of bad news for U.K. biotech.
Phase III Data With Scar Therapy Still Distant, Renovo Draws A Suitor
Pivotal results not due until 2011 – and skin peel drug needs a makeover.